Rivaroxaban Tablet, Film Coated
Product Images NDC 72603-890

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 72603-890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

556 (Rivaroxaban Fig 02)

Population Description __PK___Fold Change and 30% C1 End Stage Renal Disease Renal Impairment: - - Age: Large—. . foot Body Weight:

FDA Label Image

565 (Rivaroxaban Fig 03)

FDA Label Image

505 (Rivaroxaban Fig 09)

This data pertains to the efficacy outcomes of a study involving patients divided into various categories such as age, sex, region, weight, eGFR, medical history, stroke history, history of prior heart failure, baseline diabetes, and PAD. The study evaluated the effectiveness of Rivaroxaban compared to a placebo in preventing stroke, major cardiovascular death, or combined outcomes. The results are presented in terms of the number of patients (N) and percentage (%), and the Hazard Ratio (HR) with 95% Confidence Intervals (CI) is provided for each category, indicating whether Rivaroxaban or placebo is more beneficial.*

FDA Label Image

458 (Rivaroxaban Figure 10)

This is cumulative incidence rate data comparing Rivaroxaban to Placebo with hazard ratio information. The number of subjects at risk for each treatment group is provided at different time points, along with the days from randomization. The data appears to be part of a clinical study evaluating the efficacy and safety of Rivaroxaban compared to Placebo over time.*

FDA Label Image

569 (Rivaroxaban Figure 11)

This text seems to provide information on a study comparing the effects of Rivaroxaban and Placebo treatments with a focus on the number of subjects at risk over different days from randomization. The text includes data points such as the treatment groups, number of days, and the number of subjects in each group. It also presents specific values for the comparison between Rivaroxaban and Placebo.*

FDA Label Image

505 (Rivaroxaban Figure 12)

FDA Label Image

Str (Rivaroxaban Str)

FDA Label Image

878 (Rivaroxaban Tablets 2 5mg 60s)

This text provides information about a medication called Rivaroxaban, which contains 2.5 mg of the active ingredient. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). It is important to keep the tablets out of reach of children. The package contains 60 tablets and is manufactured by a company named Northstar. For further information, a Medication Guide is available online or by calling 1-800-206-7821.*

FDA Label Image

787 (Rivaroxaban Tablets 25 mg 180s)

Each tablet of Rivaroxaban contains 2.5 mg and should be stored at a temperature between 15°C to 30°C. This medication is manufactured by Macleods Pharmaceuticals Ltd. and is available in a package of 180 tablets. The pharmacist is advised to dispense this medication and must provide a medication guide separately to each patient. For full dosing information and prescribing details, refer to the package insert.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.